PATHOGENETIC RATIONALE FOR ALTERNATIVE THERAPY FOR MENOPAUSAL SYNDROME
- Authors: Shperling N.V.1,2, Arutyunyan A.A.1, ARUTYUNYAN A.A1
-
Affiliations:
- S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation
- International Medical Center Time
- Issue: No 6 (2015)
- Pages: 104-109
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247435
- ID: 247435
Cite item
Open Access
Access granted
Abstract
Objective. To reveal the specific characteristics of a regimen to effectively use menoril in the therapy of menopausal syndrome (MS). Subjects and methods. A total of 96 early menopause patients diagnosed with MS were followed up. The severity of MS was estimated using a questionnaire in view of neurovegetative, metabolic endocrine, and psychoemotional disorders. Questionnaire interviewing was repeated after administration of menoril. Results. A month after initiation of its therapy was marked by obvious positive changes and a dose-dependent effect - higher-dose menoril increased the probability of a positive effect and reduced the magnitude of the symptoms of MS. Conclusion. This investigation suggests that menoril is highly effective in women with different degrees of MS. The use of menoril may be regarded as a pathogenetically sound alternative to relieve MS also in women who have contraindications to menopausal hormonal therapy or in those who refuse to take hormonal agents.
Keywords
Full Text
About the authors
Natalia Vladimirovna Shperling
S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation; International Medical Center Time
Email: shperling2@yandex.ru
Doctor of Medical Sciences, Senior Researcher, Research Test Institute (Military Medicine); Obstetrician-ginecologist 195043, Russia, Saint-Petersburg, Lesoparkovaya str. 4; 194050, Russia, Saint-Petersburg, Kondratyevsky pr-t 72
Artur Albertovich Arutyunyan
S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian FederationDoctor of Medical Sciences, Professor, Head of Department, Research Test Institute (Military Medicine) 195043, Russia, Saint-Petersburg, Lesoparkovaya str. 4
A. A ARUTYUNYAN
S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian FederationDeputy Head of Department, Research Test Institute (Military Medicine) 195043, Russia, Saint-Petersburg, Lesoparkovaya str. 4
References
- Сметник В.П., Ильина Л.М., ред. Ведение женщин в пери- и постменопаузе: практические рекомендации. М., Ярославль: Литера; 2010. 221с.
- Вихляева Е.М. Климактерический синдром. В кн.: Вихляева Е.М., ред. Руководство по эндокринной гинекологии. М.: МИА; 1998: 603-50.
- Геворкян М.А., Манухин И.Б., Фаталиева К.З., Манухина Е.И. Современный подход к лечению женщин с патологическим климактерием. Медицинский совет. 2010; 3-4: 21-6.
- Ельчанинов Д.В., Аккер Л.В., Смагина И.В., Гридина А.О. Психосоматические расстройства у женщин с климактерическим синдромом в ранний период постменопаузы. Бюллетень сибирской медицины. 2009; 8(3-2): 100-3.
- Ельчанинов Д.В. Альтернативная терапия и традиционные методы лечения климактерического синдрома. В кн.: Аккер Л.В., ред. Патология климактерия. Руководство для врачей. М.: МИА; 2010: 374-401.
- Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (Протоколы). М.; 2014. 57с.
- Сметник В.П., Кулаков В.И., ред. Руководство по климактерию. М.: МИА; 2001. 685с.
- ACOG Practice Bulletin no. 141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16.
- Зайдиева Я.З. Гормонопрофилактика и коррекция системных нарушений у женщин в перименопаузе: дисс.. д-ра мед. наук. М.; 1997. 520с.
- Хамошина М.Б., Бриль Ю.А. Менопаузальные расстройства: вариативность терапевтических подходов. М.: StatusPraesens; 2014. 20с.
- Cagnacci A., Cannoletta M., Palma F., Zanin R., Xholli A., Volpe A. Menopausal symptoms and risk factors for cardiovascular disease in postmenopause. Climacteric. 2012; 15(2): 157-62.
- de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4.
- Шестакова И.Г. Возможности заместительной гормонотерапии в гинекологической практике. Гинекология. 2010; 12(1): 10-3.
- te Velde E.R., van Leusden H.A. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet. 1994; 343(8898): 654-8.
- Panay N., Hamoda H., Arya R., Savvas M. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2): 59-68.
- Jargin S.V. Phytoestrogens and other botanicals: on the problems of evidence-based evaluation. Recent Pat. Cardiovasc. Drug Discov. 2013; 8(1): 67-71.
- Tung C.W., Lin Y.C., Chang H.S., Wang C.C., Chen I.S., Jheng J.L., Li J.H. TIPdb-3D: the three-dimensional structure database of phytochemicals from Taiwan indigenous plants. Database (Oxford). 2014; 2014: 1-5. doi: 10.1093/ database/bau055.
- Williamson-Hughes P.S., Flickinger B.D., Messina M.J., Empie M.W. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause. 2006; 13(5): 831-9.
- Yao J., Zhao L., Mao Z., Chen S., Wong K.C., To J., Brinton R.D. Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor ß-selective phytoSERM treatments. Brain Res. 2013; 1514: 128-41.
- Takeuchi S., Takahashi T., Sawada Y., Iida M., Matsuda T., Kojima H. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol. Pharm. Bull. 2009; 32(2): 195-202.
- DAnna R., Cannata M.L., Atteritano M., Cancellieri F., Corrado F., Baviera G. et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007; 14(4): 648-55.
- McClain R.M., Wolz E., Davidovich A., Edwards J., Bausch J. Reproductive safety studies with genistein in rats. Food Chem. Toxicol. 2007; 45(8): 1319-32.
- Marini H., Bitto A., Altavilla D., Burnett B.P., Polito F., Di Stefano V. et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J. Clin. Endocrinol. Metab. 2008; 93(12): 4787-96.
Supplementary files
